Literature DB >> 17255259

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

Björn Engelbrekt Wahlin1, Birgitta Sander, Birger Christensson, Eva Kimby.   

Abstract

PURPOSE: Follicular lymphoma is a heterogeneous disease with variable prognosis and clinical course. We hypothesized that the presence of nonmalignant T cells in the microenvironment of the tumor may affect the outcome. EXPERIMENTAL
DESIGN: Using flow cytometry, we evaluated the T-cell subsets in the lymph node microenvironment of follicular lymphoma. All patients in South Stockholm County with indolent follicular lymphoma and with flow cytometry done on a diagnostic lymph node between 1994 and 2004 were included (N = 139). Diagnosis and grade (1, 2, and 3a) were confirmed by re-review. Flow cytometry results were reanalyzed. Lymphocyte subsets, the Follicular Lymphoma International Prognostic Index, grade, and clinical characteristics were evaluated in univariable and multivariable Cox analysis with respect to overall survival (OS) and disease-specific survival (DSS).
RESULTS: Higher CD8+ T-cell levels correlated with longer OS and DSS, independently of the Follicular Lymphoma International Prognostic Index (OS, P = 0.017; DSS, P = 0.020) and independently of all other prognostic factors (OS, P = 0.001; DSS, P = 0.004). Median OS was not reached for patients in the upper quarter of CD8+ T-cell levels (>8.6%), 10.4 years for patients in the middle half (4.2-8.6%), and 6.0 years for patients in the lower quarter (<4.2%). Furthermore, patients who had not required treatment within 6 months from diagnosis had more CD8+ T cells (P = 0.011).
CONCLUSIONS: Higher levels of CD8+ T cells predict a better prognosis, and these data support an important role for nonmalignant immune cells in the biology of follicular lymphoma. Evaluating the CD8+ T cells by flow cytometry at diagnosis may provide prognostic information.

Entities:  

Mesh:

Year:  2007        PMID: 17255259     DOI: 10.1158/1078-0432.CCR-06-1734

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

Review 1.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

2.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

3.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.

Authors:  Daphne de Jong; Ad Koster; Anton Hagenbeek; John Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine van Glabbeke
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

4.  Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.

Authors:  Marylène Lejeune; Tomás Alvaro
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

5.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Authors:  Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

Review 6.  Vaccination strategies in follicular lymphoma.

Authors:  Shibichakravarthy Kannan; Sattva S Neelapu
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

Review 7.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

8.  Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Authors:  Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-06-10       Impact factor: 6.998

9.  Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.

Authors:  Anna Israyelyan; Corinna La Rosa; Weimin Tsai; Teodora Kaltcheva; Tumul Srivastava; Lia Aquino; Jianqiang Li; Young Kim; Joycelynne Palmer; Leanne Streja; David Senitzer; John A Zaia; Andreas Rosenwald; Stephen J Forman; Ryotaro Nakamura; Don J Diamond
Journal:  Leuk Lymphoma       Date:  2013-04-30

10.  Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity.

Authors:  Shyamesh Kumar; Joram J Buza; Shane C Burgess
Journal:  Cancer Microenviron       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.